Eptigrilin 0.75mg/ml Infusion belongs to the group of medicines called 'antiplatelet agents' used to prevent the formation of blood clots, thereby reducing the chance of Myocardial infarction. Eptigrilin 0.75mg/ml Infusion is used in the treatment of Acute coronary syndrome (ACS) in both patients who need to be managed medically and also people undergoing percutaneous coronary intervention (PCI) procedures. ACS is defined as a group of serious cardiac conditions wherein the blood flow to the heart decreases due to plaque formation. Eptigrilin 0.75mg/ml Infusion is also used in the treatment of patients undergoing urgent PCI procedures and also in patients undergoing intracoronary stenting.

Eptigrilin 0.75mg/ml Infusion contains Eptifibatide, which belongs to the monoclonal anti-glycoprotein IIb/IIIa receptor antibodies class. It works by blocking the glycoprotein IIb/IIIa receptor's activity, thereby preventing platelet aggregation. This causes inhibition of fibrinogen binding, reducing the chance of blood clot formation. Eptigrilin 0.75mg/ml Infusion reduces the risk of cardiovascular events like myocardial infarction (heart attack).

Eptigrilin 0.75mg/ml Infusion may cause certain side effects, such as bleeding, nausea, headache, abdominal pain, hypotension, vomiting, dizziness, decreased platelet count, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare professional will administer Eptigrilin 0.75mg/ml Infusion. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Eptigrilin 0.75mg/ml Infusion should be avoided if you are allergic to it. It is contraindicated in patients who have active internal bleeding, history of bleeding diathesis within 30 days, thrombocytopenia, severe uncontrolled hypertension, had recent major surgery or trauma, renal failure, using another glycoprotein IIb/IIIa inhibitor, a history of cerebrovascular accident within the last two years, or recent gastrointestinal or genitourinary bleeding, intracranial neoplasm, aneurysm, as it can cause serious adverse effects. Eptigrilin 0.75mg/ml Infusion is known to cause bleeding problems. If you observe severe bleeding that cannot be controlled, it is advised to stop administering Eptigrilin 0.75mg/ml Infusion immediately. Hence, close monitoring is needed for any bleeding conditions. Talk to your doctor before receiving Eptigrilin 0.75mg/ml Infusion if you had a recent severe injury or surgery due to the risk of severe bleeding problems. If you are pregnant, planning to become pregnant, or breastfeeding, inform your doctor before taking Eptigrilin 0.75mg/ml Infusion. Eptigrilin 0.75mg/ml Infusion is not recommended for children below 12 years of age as efficacy and safety have not been established.

Eptigrilin 0.75mg/ml Infusion contains Eptifibatide, which belongs to the monoclonal anti-glycoprotein IIb/IIIa receptor antibodies class. It works by blocking the glycoprotein IIb/IIIa receptor's activity, thereby preventing platelet aggregation. This causes inhibition of fibrinogen binding, reducing the chance of blood clot formation. Eptigrilin 0.75mg/ml Infusion results in reducing the risk of cardiovascular events like myocardial infarction (heart attack) and other cardiac events.

Do not receive Eptigrilin 0.75mg/ml Infusion if you are allergic to it. It is contraindicated in patients who have active internal bleeding, history of bleeding diathesis within 30 days, thrombocytopenia, severe uncontrolled hypertension, had recent major surgery or trauma, renal failure, using another glycoprotein IIb/IIIa inhibitor, a history of cerebrovascular accident within the last two years, or recent gastrointestinal or genitourinary bleeding, intracranial neoplasm, aneurysm, as it can cause serious adverse effects. Eptigrilin 0.75mg/ml Infusion is known to cause bleeding problems. However, if you observe severe bleeding that cannot be controlled, it is advised to stop administering Eptigrilin 0.75mg/ml Infusion immediately. Hence, close monitoring of patients is needed for any bleeding conditions. Talk to your doctor before receiving Eptigrilin 0.75mg/ml Infusion if you had a recent severe injury or surgery due to the risk of severe bleeding problems. Before taking Eptigrilin 0.75mg/ml Infusion inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding due to serious foetal harm. Eptigrilin 0.75mg/ml Infusion is not recommended for children below 12 years of age as efficacy and safety have not been established. Talk to your doctor before receiving Eptigrilin 0.75mg/ml Infusion if you have/had a recent severe injury or surgery due to the risk of severe bleeding problems.